Eli Lilly's experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage ...
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...
Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...
Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...
Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...
Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...
The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
Patient selection should prioritize those with obesity and heart failure with preserved ejection fraction, as benefits for ...
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...
Eli Lilly (LLY) announced topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results